Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Clinical Trials

Antidepressants and Bone Mineral Density

Phase 3

Completed

Conditions: Bone Mineral Density Quantitative Trait Locus 7

Interventions: Drug: sertraline
Drug: citalopram
Drug: venlafaxine
Drug: reboxetine
Behavioral: control

First Posted Date: 2014-07-01

Last Posted Date: 2014-07-01

Lead Sponsor: Guiyang Medical University

Target Recruit Count: 203

Registration Number: NCT02179268

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Sertraline
Drug: Escitalopram
Drug: DCV 3DAA FDC
Drug: BMS-791325

First Posted Date: 2014-06-26

Last Posted Date: 2015-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT02175602

A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression

Phase 3

Completed

Conditions: Anxiety
Depression

Interventions: Drug: Sertraline
Behavioral: Cognitive Behavioural Therapy

First Posted Date: 2014-04-24

Last Posted Date: 2014-04-29

Lead Sponsor: University of Melbourne

Target Recruit Count: 45

Registration Number: NCT02122393

Locations: 🇦🇺
Austin Health, Melbourne, Victoria, Australia

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

Phase 4

Completed

Conditions: Obsessive-Compulsive Disorder
Anxiety Disorders
Mental Disorders

Interventions: Behavioral: Exposure and Response Prevention
Drug: Fluoxetine
Drug: Sertraline
Drug: Paroxetine
Drug: Citalopram
Drug: Fluvoxamine

First Posted Date: 2013-12-30

Last Posted Date: 2022-09-09

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 78

Registration Number: NCT02022709

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

Phase 2

Terminated

Conditions: Anxiety Disorder of Adolescence

Interventions: Drug: Sertraline
Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2013-11-07

Last Posted Date: 2016-05-16

Lead Sponsor: Yale University

Target Recruit Count: 1

Registration Number: NCT01977729

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States

Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Sertraline

First Posted Date: 2013-07-11

Last Posted Date: 2017-07-21

Lead Sponsor: Vanderbilt University

Target Recruit Count: 31

Registration Number: NCT01896934

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Interpersonal Psychotherapy for Treatment Resistant Depression

Not Applicable

Conditions: Treatment Resistant Depression

Interventions: Other: IPT+ antidepressant drugs
Drug: fluoxetine
Drug: sertraline
Drug: paroxetine
Drug: Citalopram
Drug: escitalopram
Drug: fluvoxamine
Drug: Venlafaxine
Drug: Duloxetine
Drug: Lithium
Drug: Bupropion
Drug: Risperidone
Drug: tranylcypromine
Drug: Imipramine
Drug: amitriptyline
Drug: Clomipramine
Drug: nortriptyline
Drug: trazodone
Drug: Mirtazapine
Drug: sulpiride

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

Phase 4

Terminated

Conditions: Sexual Dysfunction
Major Depressive Disorder

Interventions: Drug: Vilazodone
Drug: Sertraline

First Posted Date: 2013-05-17

Last Posted Date: 2016-08-25

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 4

Registration Number: NCT01856127

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States